Scisparc exploring psychedelics as possible avenue to expand its ip portfolio

Tel aviv, israel, jan. 11, 2022 /prnewswire/ -- scisparc ltd. (nasdaq: sprc), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "company"), announced that it has begun to examine the possibility of including psychedelic compounds as potential drug candidates for its intellectual property portfolio.
SPRC Ratings Summary
SPRC Quant Ranking